A novel knock-in mouse model of CAPS that develops amyloidosis: therapeutic efficacy of proton pump inhibitors

Add time:07/13/2019    Source:sciencedirect.com

BackgroundCryopyrin associated periodic syndromes (CAPS) are a group of autoinflammatory diseases linked to gain-of-function mutations in the NLRP3 gene which cause uncontrolled IL-1β secretion. Proton pump inhibitors (PPIs), commonly used as inhibitors of gastric acid production, also display anti-inflammatory properties, protect mice from sepsis, and prevent IL-1β secretion by CAPS monocytes.

We also recommend Trading Suppliers and Manufacturers of macrophage capping protein (cas 148412-71-9). Pls Click Website Link as below: cas 148412-71-9 suppliers

Prev:Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma
Next:Synthesis and structure–activity relationships of N-(4-amino-2,6-diisopropylphenyl)-N’-(1,4-diarylpiperidine-4-yl)methylureas as anti-hyperlipidemic agents)